<DOC>
	<DOCNO>NCT01759823</DOCNO>
	<brief_summary>The purpose study improve blood glucose level type 2 diabetic patient .</brief_summary>
	<brief_title>Bone Marrow Derived Stem Cell Transplantation T2DM</brief_title>
	<detailed_description>We hypothesize Autologous bone marrow derive stem cell would expand culture subsequent transplant pancreas patient T2DM , age 30 - 70 year triple oral hypoglycemic agent failure insulin ( &gt; 0.4 U/ kg body weight/day ) lead abolition reduction insulin requirement equal 50 % patient period 6 month . It assume stem cell patient lead increased angiogenesis , secretion various cytokine upregulation pancreatic transcription factor Vascular endothelial growth factor ( VEGF ) create micro-environment support beta cell/resident stem cell activation survival .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Patients type 2 diabetes mellitus 30 70 year age . Failure triple oral hypoglycemic agent stable dos insulin least 3 month . On vildagliptin , pioglitazone metformin least 3 month along Insulin maintain euglycemia . HbA1c &lt; 7.5 % . Insulin requirement â‰¥0.4 IU/kg/d . GAD antibody negative status . Patients type 1 diabetes mellitus secondary diabetes . Patients serum creatinine &gt; 1.5 mg/dl . Abnormal liver function test ( define value transaminases &gt; 3 time upper value normal serum bilirubin high normal reference value laboratory ) . History cholecystitis/ cholelithiasis/ cholecystectomy Seropositivity HIV , HBsAg hepatitis C virus ( HCV ) . History myocardial infarction unstable angina previous 3 month . History malignancy Patients active infection .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>